NEW YORK--(BUSINESS WIRE)--OMRIX Biopharmaceuticals, Inc. (“OMRIX” or the “Company”) (NASDAQ: OMRI), a commercial-stage biopharmaceutical company that develops and markets biosurgical and antibody-based products, announced today that it will provide Thrombin Phase 3 Clinical Trial results on Monday, October 16, 2006. The Company will issue a press release before the open of U.S. financial markets and host a live conference call and webcast at 10:00 am ET (7:00 am PT) also on Monday, October 16, 2006.
